tradmap

XBIT XBiotech Inc.

$1.88 -2.59%

Data as of close

Healthcare · Pharmaceutical Preparations

XBiotech Inc. (XBIT) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $57 million. Shares last traded at $1.88, 45.2% below their 52-week high. Over the past year the stock is down 23.6%. Revenue declined 100.0% year over year.

Market Cap
$57M
Shares Out
30.5M
EPS (TTM)
-$1.49
P/E (TTM)*
—
P/S Ratio
—
P/B Ratio
0.45
Dividend / Share
—
Dividend Yield
—
52-Week High
$3.43
52-Week Low
$1.82
Volume (venue)
2,177
Avg Vol (3m, venue)
1,091.476

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
+3.30%
1M
-14.35%
3M
-15.70%
6M
-26.13%
YTD
-20.00%
1Y
-23.58%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
36.52
SMA (50)
$2.15
SMA (200)
$2.33
Price vs SMA50
-12.42%
Price vs SMA200
-19.29%
ATR (14)
$0.07

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$0
Net Income
-$45M
Gross Margin
—
Operating Margin
—
Net Margin
—
Return on Equity
-35.1%
Return on Assets
-33.8%
Current Ratio
33.15
Debt / Equity
0.04
Revenue Growth (YoY)
-100.0%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
FY 2025 -$1.49 2026-03-13
FY 2024 -$1.26 2025-03-18
FY 2023 -$0.81 2024-03-15
FY 2022 -$1.08 2023-03-15
FY 2021 -$0.58 2022-03-15
FY 2020 -$0.36 2021-03-16

Full earnings history →

Pharmaceutical Preparations peers

XBIT vs 14 industry peers (Pharmaceutical Preparations), by market cap. Data as of close

1–14 of 14
LLYLilly (Eli)$1.33T48.1315.3531.9%-0.28%
JNJJohnson & Johnson$652.2B40.526.5716.2%-0.82%
ONCBeone Medicines Ltd.$533.8B814.0587.0910.7%-2.48%
ABBVAbbVie$510.3B80.877.939.8%-2.05%
MRKMerck$366.4B115.465.504.8%-0.22%
ABTAbbott Laboratories$192.1B30.614.2613.9%+3.81%
PFEPfizer$175.0B40.412.756.8%+0.69%
VRTXVertex Pharmaceuticals$144.5B32.8011.4835.0%+1.96%
BMYBristol Myers Squibb$128.8B13.942.5818.5%+0.90%
REGNRegeneron Pharmaceuticals$99.4B20.645.8928.5%+3.63%
TEVATeva Pharmaceutical Industries Ltd$47.4B67.142.744.1%-3.35%
ZTSZoetis$34.4B13.143.6127.5%+4.35%
RPRXRoyalty Pharma Plc$29.6B36.3511.6832.1%-0.98%
ROIVRoivant Sciences Ltd.$25.9B—3441.87—-2.76%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.